NCT03004105撤回2 期
Phase II Trial of Immunotherapy With Durvalumab (MEDI4736) With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Progression Free Survival
研究概览
简要总结
The goal of this clinical research study is to learn if MEDI4736 given in combination with selumetinib can help to control advanced lung cancer.
The safety of this drug combination will also be studied.
详细描述
Study Groups:
If participant is found to be eligible to take part in this study, participant will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. This is done because no one knows if one study group is better, the same, or worse than the other group.
- If participant is in Group 1, participant will take selumetinib 2 times each day.
- If participant is in Group 2, participant will take selumetinib 2 times each day on Days 1-7 and 15-22 of each study cycle.
All participants will also receive MEDI4736.
Study Drug Administration:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed recurrent non-small cell lung cancer not amendable to curative intent therapy or stage IV NSCLC.
- •Known KRAS mutation status by CLIA certified test. Patients in the safety run-in are not required to have a tumor with mutant KRAS. In the randomized portion of the trial, only patients with KRAS mutation are eligible.
- •Documented progression following at least one line of chemotherapy for metastatic or recurrent disease, or progression within 6 months of receiving adjuvant chemotherapy or concurrent chemotherapy for early stage or locally advanced disease.
- •Biopsy accessible disease and willingness to undergo tumor biopsy.
- •Measurable disease by RECIST 1.
- •Age>/= 18 years.
- •ECOG performance status 0 or
- •Ability to take pills by mouth.
- •Patients must have normal organ and marrow function as defined: leukocytes >/=3,000/mcL, absolute neutrophil count >/=1,500/mcL, platelets >/=100,000/mcL, hemoglobin >/9.0g/dL, total bilirubin </=1.5 x upper limit of normal (ULN) (higher is allowed if in the setting of known Gilbert's disease), AST(SGOT)/ALT(SGPT) </=2.5 x institutional upper limit of normal or </=5 x ULN if liver metastases are present, Alkaline phosphatase </=3.5 x institutional upper limit of normal or <6 x ULN if liver metastases are present, creatinine clearance >/=50 mL/min/1.73^2 by Cockcroft-Gault equation (creatinine clearance= ([140-age]x body mass)/(plasma creatinine x 72) x gender correction factor) or by 24-hour urine collection.
- •Brain metastases are allowed, as long as they are stable and do not require treatment with anticonvulsants or escalating doses of steroids.
- •Females of childbearing potential must have a negative serum pregnancy test and must agree to use adequate contraception for the duration of the study and six months after. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Continued in #12
- •Continued from #11: a) Acceptable effective methods of contraception for women include implants, injectables, combined oral contraceptives, some intrauterine devices/systems and sterilization including vasectomy of the partner, all being used in combination with barrier methods of contraception (e.g. condoms). b) True sexual abstinence is also an acceptable method of contraception. Continued in #13
- •Continued from #12: Women will be considered post-menopausal if they have been amenorrheic for the past 12 months without an alternative medical cause. The following age-specific requirements must also apply: i.)Women < 50 years old: they would be considered post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of exogenous hormonal treatments. The levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) must also be in the post-menopausal range (as per the institution). ii.)Women >/= 50 years old: they would be consider post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of all exogenous hormonal treatments, or have had radiation-induced oophorectomy with the last menses > 1 year ago, or have had chemotherapy-induced menopause with >1 year interval since last menses, or have had surgical sterilisation by either bilateral oophorectomy or hysterectomy.
- •Non-sterilized males who are sexually active with a female partner of childbearing potential must use adequate contraception for the duration of the study and 90 days after the last dose of study medication. a) Acceptable methods of contraception for men include the use of condoms with spermicidal foams/gels or prior vasectomy. b) True sexual abstinence is also an acceptable method of contraception.
- •Ability to understand and the willingness to sign a written informed consent document.
- •Have adequate renal function, with a GFR of >/= 50ml/min by the Cockcroft-Gault formula or by 24 hour urine collection.
排除标准
- •Have received or are receiving an investigational medicinal product (IMP) or other systemic anticancer treatment within 4 weeks prior to the first dose of study treatment, or within a period during which the IMP or systemic anticancer treatment has not been cleared from the body (e.g. a period of 5 'half-lives'), whichever is the most appropriate and as judged by the investigator.
- •Current or prior use of immunosuppressive medication within 14 days of the 1st dose of durvalumab, with the exception of intranasal and inhaled corticosteroids or oral corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- •Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.
- •Receipt of radiation therapy within 4 weeks prior to starting study treatment. Limited field of radiation for palliation at any time prior to the start of study treatment is acceptable if: i.) The lung is not in the radiation field ii.) The irradiated lesions are not used as target lesions.
- •Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab.
- •Prior treatment with a MEK, Ras, or Raf inhibitor, or CTLA4 inhibitor.
- •Patients who are receiving any other investigational agents.
- •Have any unresolved chronic toxicity with CTCAE grade >/= 2, from previous anticancer therapy, except for alopecia.
- •Known hypersensitivity to selumetinib or durvalumab or any excipient or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or durvalumab.
- •Active or prior documented autoimmune disease within the past 3 years. Patients with a history of vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
- •Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis).
- •Have known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, has been treated with surgery and / or radiation, and has been stable without requiring corticosteroids nor anti-convulsant medications for at least 4 weeks prior to the first dose of study medication.
- •Known history of previous clinical diagnosis of tuberculosis.
- •History of primary immunodeficiency.
- •History of organ transplant requiring therapeutic immunosuppression.
- •Cardiac conditions as follows: i.) Mean QT interval corrected for heart rate (QTc) >/=450 ms calculated from 3 ECGs using Fredericia's formula [QTcF] or other factors that increase the risk of QT prolongation. ii.) Uncontrolled hypertension (BP >/= 150/95 despite optimal medical therapy). iii.) Acute coronary syndrome within 6 months prior to starting treatment. iv.) Uncontrolled Angina - Canadian Cardiovascular Society grade II-IV despite medical therapy. v.) Symptomatic heart failure NYHA Class II-IV, prior or current cardiomyopathy, or severe valvular heart disease. - Criteria continued in #17
- •Continued from #16: vi.) Prior or current cardiomyopathy including but not limited to the following: a) known hypertrophic cardiomyopathy b) known arrhythmogenic right ventricular cardiomyopathy c) previous moderate or severe impairment of left ventricular systolic function (LVEF <45% on echocardiography or equivalent on MuGA) even if full recovery has occurred. vii.) Baseline Left ventricular ejection fraction (LVEF) below the LLN or <55% measured by echocardiography or institution's LLN for MUGA. viii.) Severe valvular heart disease. ix.) Atrial fibrillation with a ventricular rate > 100 bpm on ECG at rest.
- •Ophthalmologic conditions as follows: i.) Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy (CSR) or retinal vein occlusion. ii.) Intraocular pressure (IOP) > 21 mmHg or uncontrolled glaucoma (irrespective of IOP).
- •Any gastrointestinal disorder expected to limit absorption of selumetinib
- •History of another primary malignancy within 5 years prior to starting study treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ
- •Recent major surgery within 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access.
- •Uncontrolled intercurrent illness including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including hepatitis B, hepatitis C, HIV, and active clinical tuberculosis), active bleeding diatheses or renal transplant; ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant or breastfeeding women.
- •Receiving or have received systemic anti-cancer therapy within 4 weeks prior to starting study treatment (6 weeks for nitrosoureas, mitomycin, and suramin), or any anticancer therapy which has not been cleared from the body by the time of starting study treatment.
- •Have evidence of any other significant clinical disorder or laboratory finding that, as judged by the investigator, makes it undesirable for the patient to participate in the study.
- •Have refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would adversely affect the absorption / bioavailability of the orally administered study medication.
- •Are male or female patients of reproductive potential and, as judged by the investigator, are not employing an effective method of birth control.
- •Patient weight less than 30 kg.
研究组 & 干预措施
Intermittent Arm - Selumetinib + Durvalumab
Experimental
Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
干预措施: Selumetinib (Drug)
Intermittent Arm - Selumetinib + Durvalumab
Experimental
Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
干预措施: Durvalumab (Drug)
Intermittent Arm - Selumetinib + Durvalumab
Experimental
Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
干预措施: Phone Calls (Behavioral)
Safety Run In
Experimental
Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.
During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status.
干预措施: Selumetinib (Drug)
Safety Run In
Experimental
Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.
During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status.
干预措施: Durvalumab (Drug)
Continuous Arm - Selumetinib + Durvalumab
Experimental
Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.
Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
干预措施: Selumetinib (Drug)
Continuous Arm - Selumetinib + Durvalumab
Experimental
Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.
Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
干预措施: Durvalumab (Drug)
Continuous Arm - Selumetinib + Durvalumab
Experimental
Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.
Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
干预措施: Phone Calls (Behavioral)
结局指标
主要结局
Progression Free Survival
时间窗: 42 months
Progression-free survival (PFS) defined as the duration of time from start of treatment for patients in the safety run-in and from randomization for patients who are randomized to time of progression or death, whichever occurs first.
次要结局
- Response Rate(Every 8 weeks for 1 year)
研究者
相似试验
撤回
2 期
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaBorderline Resectable CarcinomaBiliary Tract CancerNCT06017297Georgetown University28
已完成
2 期
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT02904954Weill Medical College of Cornell University60
已完成
2 期
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic CholangiocarcinomaUnresectable Intrahepatic CholangiocarcinomaNCT04301778Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins5
已完成
1 期
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8NCT03581487M.D. Anderson Cancer Center40
已完成
2 期
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerMalignant Neoplasms of Digestive OrgansColorectal CancerColon CancerNCT03428126M.D. Anderson Cancer Center29